Clinical Trial Excellence: Shaping Markets Through Early Communication of Clinical Trial Data

CHAPEL HILL, N.C., May 25, 2007 /PRNewswire/ -- With enormous investments and the success of a pharmaceutical product at play, pharmaceutical firms need to develop effective strategies for communicating clinical trial results early. Companies that master their communication planning and execution will gain a significant advantage in the marketplace.

According to research and consulting firm Best Practices, LLC, successful companies create communication plans long before the interim or final results for a landmark trial are available. For example, one surveyed company establishes its integrated communication strategy as early as Phase I. In addition, leading companies also develop early scenario planning for good, bad, neutral and most likely study results.

"From Breakthrough to Blockbuster: Best Practices in Communicating Clinical Trial Results" - available with a complimentary study excerpt at http://www3.best-in-class.com/rr805.htm - examines the most effective practices for communicating clinical trial results to physicians, the managed care community, investors and consumers.

The extensive report includes over 100 best practices, metrics and narratives; a clinical communication toolkit that can help executives with the development of a communication plan or activity checklist to prepare for post- launch communication tactics. Study findings include:

    -- Communicating to Physicians: 60% of benchmarked pharmaceutical

       companies begin communicating to physicians more than six months prior

       to the drug launch. However, executives also warn that too early

       communication might trigger the opposite.

    -- Communicating to Managed Care Organizations: The information

       requirements are significantly different from the needs of physicians,

       because in addition to drug indications MCOs are also looking for

       complex pricing information. One benchmarked company involves pharmacy

       directors in ancillary studies that look at utilization data,

       activities necessary for government or private payers and cost-benefit-

       ratios for the drug.

    -- Communicating to Consumers: One executive identified tailoring messages

       to community and patient advocacy groups by therapeutic area as the

       most innovative public relations activity. For example, the company

       hosts separate events for consumer and advocacy leaders in the

       community.

Download the report excerpt online at http://www3.best-in-class.com/rr805.htm to view sample best practices and performance metrics.

To drill down on the numerous metrics presented in this report more deeply contact our Solution Specialists at (919) 403-0251 or . bestpractices@best-in-class.com

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for nearly 15 years; our clients include 43 out of the top 50 pharmaceutical companies.

CONTACT: Kimberly Hardin of Best Practices, LLC, +1-919-767-9221, or khardin@best-in-class.com

Web site: http://www3.best-in-class.com/rr805.htm/http://www.best-in-class.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: May 2007

View comments

Hide
(web2)